Lose Excess Weight. Protect Your Health. Build Something Sustainable.
Modern incretin-based medications have changed obesity treatment because they target biological pathways involved in hunger, fullness, glucose regulation, and energy balance.
But medication is only one part of the process. The goal should be to reduce excess adiposity while preserving muscle, improving metabolic health, supporting good nutrition, and building a strategy capable of maintaining the result.
Semaglutide • Tirzepatide • RetatrutideBody Weight Is Biologically Regulated
The brain receives a constant stream of information about available energy, stored energy, food intake, glucose levels, gastrointestinal activity, hormones, stress, sleep, and the body’s current metabolic needs.
These signals influence hunger, satiety, food reward, portion size, glucose regulation, and energy balance.
Hunger & Satiety
Gut-derived hormones communicate with the brain to influence appetite, meal size, fullness, and food intake.
Glucose Regulation
Insulin secretion, insulin sensitivity, glucagon, skeletal muscle, and liver metabolism all influence metabolic health.
Adipose Tissue
Body fat is metabolically active tissue that communicates with the brain, immune system, liver, muscle, and endocrine system.
Muscle & Metabolism
Skeletal muscle supports physical function, glucose disposal, metabolic health, strength, and long-term weight maintenance.
Obesity Is More Than a Calorie-Counting Problem
Energy balance still matters, but hunger, appetite regulation, metabolic adaptation, medications, sleep, genetics, environment, and neuroendocrine signaling strongly influence how difficult it is to achieve and maintain a calorie deficit.
How Medical Weight Management Works
Reduce Hunger
Incretin-related medications influence brain and gastrointestinal pathways involved in appetite and food intake.
Improve Satiety
Patients may feel satisfied with smaller portions and remain full longer after eating.
Improve Metabolic Health
Losing excess adiposity can improve glucose regulation, cardiometabolic risk factors, mobility, and other obesity-related health conditions.
Protect Lean Mass
Weight loss includes both fat and lean tissue. Protein intake, resistance training, activity, and appropriate nutrition help protect muscle.
Metabolic Weight-Management Medications
Semaglutide
Semaglutide mimics signaling through the GLP-1 receptor, a pathway involved in appetite, satiety, glucose-dependent insulin secretion, glucagon regulation, and gastrointestinal function.
Tirzepatide
Tirzepatide combines activity at both the GIP and GLP-1 receptors within a single molecule.
This dual-incretin approach influences appetite, food intake, insulin secretion, glucose regulation, and metabolic signaling.
Retatrutide
Retatrutide is an investigational single molecule designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon.
The addition of glucagon-receptor activity makes its metabolic profile distinct from semaglutide and tirzepatide.
More Receptors Does Not Automatically Mean “Better”
Adding receptor targets changes pharmacology, but effectiveness, tolerability, safety, individual response, medical history, and long-term evidence all matter when evaluating a medication.
How the Three Approaches Differ
A Simple Way to Remember It
Semaglutide: primarily appetite and metabolic regulation through GLP-1.
Tirzepatide: combines GLP-1 with GIP signaling.
Retatrutide: adds glucagon-receptor activity to the GIP/GLP-1 platform and remains under clinical development.
What Have Major Clinical Trials Shown?
Semaglutide
~14.9%Average body-weight reduction at 68 weeks in the pivotal STEP 1 trial using semaglutide 2.4 mg in adults without diabetes.
Tirzepatide
Up to ~20.9%Average body-weight reduction at 72 weeks in SURMOUNT-1 at the highest studied tirzepatide dose in adults without diabetes.
Retatrutide
Up to ~28.3%Company-reported Phase III TRIUMPH-1 topline result at 80 weeks at the highest studied dose in adults without diabetes. Retatrutide remains investigational.
Do Not Compare These Percentages Like a Head-to-Head Trial
These studies involved different populations, durations, protocols, doses, and statistical analyses. Cross-trial percentages can help illustrate the development of obesity pharmacotherapy, but they do not prove how one medication would perform against another in the same individual.
Retatrutide Update — 2026
Lilly has now announced positive results from multiple Phase III TRIUMPH studies. In TRIUMPH-1, the highest studied dose produced an average 28.3% body-weight reduction at 80 weeks.
These are encouraging late-stage clinical results, but retatrutide remains investigational and has not yet received FDA approval.
Weight Loss Is Only One Outcome
Cardiometabolic Risk
Reducing excess adiposity can improve blood pressure, triglycerides, glucose regulation, inflammation, waist circumference, and other cardiometabolic risk factors.
Cardiovascular Health
Semaglutide has an FDA-approved cardiovascular-risk-reduction indication for certain adults with established cardiovascular disease and overweight or obesity.
Obstructive Sleep Apnea
Tirzepatide is FDA approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Mobility & Quality of Life
Appropriate weight reduction may make movement easier, reduce mechanical load, improve physical function, and help patients participate more fully in exercise and everyday life.
Protect Muscle While Losing Weight
Any substantial weight loss can include some loss of lean tissue. That makes preservation of skeletal muscle an important part of a well-designed weight-management plan.
Prioritize Protein
Reduced appetite can make it surprisingly difficult to consume adequate protein. Protein-rich foods should remain a deliberate part of the nutrition plan.
Resistance Training
Muscle needs a reason to stay. Progressive resistance exercise provides an important mechanical signal for maintaining strength and lean tissue during weight loss.
Stay Physically Active
Walking, aerobic exercise, recreational activity, and regular movement support cardiovascular fitness, metabolic health, and maintenance of physical function.
Avoid Excessive Restriction
Severe appetite suppression is not necessarily the goal. Patients still need enough nutrition, protein, fluids, micronutrients, and energy to function and recover.
Better Body Composition Is the Goal
A successful plan should aim to reduce excess adiposity while preserving muscle, strength, metabolic function, and nutritional adequacy.
Safety & Medical Considerations
GI Effects
Nausea, vomiting, diarrhea, constipation, abdominal symptoms, and reduced appetite are common with incretin-based therapies.
Hydration
Persistent vomiting or diarrhea can cause dehydration and contribute to acute kidney injury.
Gallbladder & Pancreas
FDA-approved semaglutide and tirzepatide labeling includes warnings related to acute gallbladder disease and pancreatitis.
Nutrition
Reduced intake can create inadequate protein, micronutrient, or total-energy intake if nutrition is not intentionally managed.
Thyroid C-Cell Tumor Boxed Warning
FDA-approved semaglutide and tirzepatide products carry boxed warnings because thyroid C-cell tumors occurred in rodents. It is unknown whether this risk translates to humans.
These medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Surgery & Anesthesia
These medications can affect gastric emptying. Patients should tell their medical and anesthesia teams that they use an incretin-based medication before planned surgery or procedures requiring anesthesia or deep sedation.
FDA & Regulatory Status
Semaglutide
FDA-approved Wegovy formulations are indicated for chronic weight management in appropriate patients. Wegovy also has additional FDA-approved indications in defined populations, including cardiovascular-risk reduction.
Tirzepatide
Zepbound is FDA approved for chronic weight management in qualifying adults and for moderate-to-severe obstructive sleep apnea in adults with obesity.
Retatrutide
Retatrutide remains investigational. Phase III trials have produced positive topline results, but there is currently no FDA-approved retatrutide medication for public use.
Important Retatrutide Distinction
Clinical-trial retatrutide is manufactured and administered under controlled research conditions. Products marketed outside those trials should not be represented as an FDA-approved retatrutide medication.
The Foundations of Sustainable Weight Management
The ideal outcome is not to eat as little as possible. It is to use improved appetite regulation as an opportunity to build a healthier metabolic environment.
Ready to Work on Your Weight & Metabolic Health?
Schedule a personalized wellness consultation to discuss your weight history, metabolic health, body composition, medications, nutrition, activity, goals, and appropriate treatment options.
Book a Wellness ConsultationSelected Scientific References
STEP 1 randomized trial of once-weekly semaglutide in adults with overweight or obesity.
View on PubMed →
SURMOUNT-1 randomized trial of tirzepatide in adults with obesity or overweight.
View on PubMed →
Phase II trial of the GIP/GLP-1/glucagon receptor agonist retatrutide in adults with obesity.
View Study →
TRIUMPH-1 Phase III topline results for retatrutide.
View Phase III Update →
Current FDA labeling for semaglutide weight-management therapy.
View Current Label →
Current FDA labeling for tirzepatide chronic weight management and obstructive sleep apnea.
View Current Label →